For example, in ovarian cancer, the combination of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab and the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib [6], as well as the PARP inhibitor niraparib [7], prolongs progression-free survival (PFS) after initial treatment with platinum-based chemotherapy. Here, VEGFA is linked to ovarian cancer.